Clonal haematopoiesis and risk of chronic liver disease.

TitleClonal haematopoiesis and risk of chronic liver disease.
Publication TypeJournal Article
Year of Publication2023
AuthorsWong, WJ, Emdin, C, Bick, AG, Zekavat, SM, Niroula, A, Pirruccello, JP, Dichtel, L, Griffin, G, Uddin, MMesbah, Gibson, CJ, Kovalcik, V, Lin, AE, McConkey, ME, Vromman, A, Sellar, RS, Kim, PG, Agrawal, M, Weinstock, J, Long, MT, Yu, B, Banerjee, R, Nicholls, RC, Dennis, A, Kelly, M, Loh, P-R, McCarroll, S, Boerwinkle, E, Vasan, RS, Jaiswal, S, Johnson, AD, Chung, RT, Corey, K, Levy, D, Ballantyne, C, Ebert, BL, Natarajan, P
Corporate AuthorsNHLBI TOPMed Hematology Working Group
Date Published2023 Apr
KeywordsAnimals, Clonal Hematopoiesis, Fibrosis, Hepatitis, Inflammation, Liver Cirrhosis, Mice, Non-alcoholic Fatty Liver Disease

Chronic liver disease is a major public health burden worldwide. Although different aetiologies and mechanisms of liver injury exist, progression of chronic liver disease follows a common pathway of liver inflammation, injury and fibrosis. Here we examined the association between clonal haematopoiesis of indeterminate potential (CHIP) and chronic liver disease in 214,563 individuals from 4 independent cohorts with whole-exome sequencing data (Framingham Heart Study, Atherosclerosis Risk in Communities Study, UK Biobank and Mass General Brigham Biobank). CHIP was associated with an increased risk of prevalent and incident chronic liver disease (odds ratio = 2.01, 95% confidence interval (95% CI) [1.46, 2.79]; P 

Alternate JournalNature
PubMed ID37046084
PubMed Central ID4624443
Grant ListG12 MD007597 / MD / NIMHD NIH HHS / United States